Platelet activating factor (PAF) is known to produce a wide veriety of hemodynamic effects .
Introduction
In recent years, great deal of attention has been given to the interaction between platelets and the vascular endothelium.
It is generally accepted that abnormalities in platelet-blood vessel interaction very often cause vascular endothelial dysfunction and/or vascular thrombosis (Vanhoutte at al., 1985; Crowley at al., 1994; Yang et al., 1994) . Furthermore, among sub stances liberated from platelets stimulated by platelet agonists there are several vasoactive agents participating in blood vessel contractility (Witte et al., 1978; Kaplan at al ., 1979; Brash 1985; Bossant at al., 1990; Henson 1990) . Some vasoactive substances released from activat ed platelets are closely affected by the agonists (Vanhoutte et al., 1985; Yang at al., 1994) .
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Platelet activating factor (PAF), a platelet agonist, has been characterized as 1-o-alky1-2 -acetyl-sn-glycero-3-phosphocholine (Blank et al., 1979; Demopoulos et al., 1979) , having diverse hemodynamic effects, including constriction of the pulmonary (Heffner et al., 1983) and coronary vasclature (De Fily et al., 1996) , enhancement of vascular permeability (Voelkel et al., 1982 Jancar et al., 1991 and hypotensive action (Blank et al., 1979 Bessin et al., 1983 Otsuka et al., 1985 Matsuda et al., 1993 . In addition, PAF is generated by different cell types, including vascular endothelial cells (Zimmerman et al., 1985) and platelets (Hanahan et al., 1985) , and then activates platelets and is followed by modulation of platelet-mediated vascular responses. Arterial preparation and perfusing conditions A arterial segment was dissected from the proximal portion of the rabbit ear central artery. This segment, about 2.7cm long, was separately cannulated at the proximal and distal ends with polyethylene tubing, and it was mounted in a nearly 5ml organ bath on a horizontal plane apparatus. This preparation was then perfused with a modified Krebs solution (Michibayashi 1992 ) by means of a roller pump delivering a constant flow of 3ml/min. A suitable concentration of NA (0.1ml), freshly prepared in normal Krebs solution, was injected as a bolus into a rubber tube connected to the central arterial cannula, and then vasocon strictive response to noradrenaline (NA-R) was observed as a perfusion pressure change (mmHg). This change in perfusion pressure was recorded on a kymographion using a mercury manometer.
In examining the effect of PRP with and without PAF on NA-R and basal perfusion pressure (BPP), autologous PRP was infused into the perfusion system at a rate of 3 ml/hr with a Micro Infusion Pump (SP-5, Nipro Co. Ltd, Tokyo, Japan). Under these conditions, the flow rate was increased about one sixtieth of that during perfusion of the modified normal Krebs solution (normal test solution) alone (about 0.05ml/min) more than that of pre-infusion state, while this infusion rate of normal test solution without PRP did not elicit any elevation of BPP.
Platelet aggregation was induced by the addition of PAF (5.0 to 50ng/ml) into the syringe containing PRP. Immediately after this, PRP with PAF was infused into the perfusing circuit.
In examining the action of tetrodotoxin (TTX) on NA-R in the presence of PRP with PAF , preparation was pretreated by TTX (10-7g/ml) for 30min before infusion of PRP with PAF. Subsequently, the effect of TTX on NA-R was examined under the conditions perfusing TTX continuously.
The drugs used were: 3.8% sodium citrate (Midorijyuzi, Japan), platelet activating factor
(1-o-alkyl-2-acetyl-sn-glycero-3-phosphocholine, Avanti Polar Lipids, Inc., U.S.A.), collagen (Worthington Biochemical Co., U.S.A.), bovine serum albumin (Chibachikusan, Japan), in domethacin (SIGMA), (-) arterenol bitartrate salt (noradrenaline , SIGMA) tetrodotoxin (San kyo, Japan).
Statistical analysis: All data were analyzed using the F-test and a difference of p<0 .05 was considered to be significant. In the former, 5 ng of NA was repeatedly injected as a bolus every 10 min during infusion of PRP with PAF, 50ng/ml. Similarly, 50ng of NA was injected during infusion of PRP with PAF, 10 ng/ml, in the latter. Unstable elevation of BPP was observed under both experimental conditions. In Table 1A , individual experimental conditions and results of NA-R and BPP in the presence of platelets activated by PAF are represented.
Results

Responsiveness
Amounts of NA applied as a bolus were in the range of 5 to 50ng. Also, concentrations of PAF applied to the syringe containing PRP ranged from 5 to 50ng/ml.
Further, infusion rates of PRP with and without PAF ranged from 0.6 to 3.0ml/hr. Such experimental method conditions and results are summerized in Table 1B . According to the present observations, NA-R was of two different types, i.e., gradually attenuated response and gradually augmented or constant response. In many instances, low doses of NA elicited the former response and high doses of NA were associated Fig. 2A .
Gradually attenuated responses to noradrenaline during infusion of PRP with PAF At first, NA-R was carried out during perfusion of normal test solution, and then during infusion of PRP into the perfusion circuit. Finally, NA-R re petitively performed 3 times at 10min intervals during infusion of PRP with PAF. The first response to NA during infusion of PRP with PAF was appar ently and significantly increased in comparison with the response to NA during infusion of PRP alone. Follow ing this, NA-R. was gradually attenuated.
Results (P value) of statis tical comparison are shown in this figure. The amount of NA applied in these experiments was within the range of 5 to 25ng. Numbers of deter minations are given in parenthesis. with the latter. Moreover, the type of NA-R was indifferent to the amount of PAF and the infusion rate of PRP with PAF.
Gradually attenuated responses to NA are represented as a graph in Fig .2A . NA-R (ordinate) values were plotted as the relative responses (mmHg) during infusion of PRP alone.
The first response to NA in the presence of PRP with PAF was apparently and significantly increased in comparison to the response during infusion of PRP alone . Following this, NA-R was gradually attenuated. When compared with the initially augmented response to NA, both Tsutomu MICHIBAYASHI Fig. 3 . Effect of tetrodotoxin on NA-R in the presence of PRP with PAF In this experiment, the perfused arterial preparation was pretreated with TTX, 10-7g/ml, for 30min before infusion of PRP with PAF. Following this, the effect of TTX on NA R was examined under the conditions perfusing TTX continuously. PAF (I) and PAF (II) represent the concentrations of PAF in PRP of 5ng/ml and 50ng/ml, respectively.
the second and the third responses were significantly reduced.
In In contrast, PGI2 and nitric oxide derived from vascular endothelium function entirely as antithrombotics (Vanhoutte et al ., 1985; Zimmerman et al., 1985; Yang et al ., 1994) .
Vascular endothelial dysfunction accompanied by platelet activation develops very often in pathological conditions and/or diseases such as atherosclerosis, hypertension, vasculitis, col lagen disease, and disseminated intravascular coagulation (Vanhoutte et al ., 1985; Zimmerman et al.,1985; Yang et al., 1994; Gerritsen et al., 1996) . Since mechanisms of abnormal platelet-blood vessel interactions causing vascular damage differ in vascular diseases, it seems to be very important to elucidate their mechanisms for the sake of preventing individual angiopathies. The present study,focusing on PAF among many platelet agonists , was carried out in an attempt to investigate PAF action on platelet-blood vessel interaction using an isolated perfused arterial preparation of rabbit ear central artery . PAF is a ubiquitous bioactive phospholipid, the production of which occurs not only through activation of platelets by platelet agonists (Hanahan et al., 1985) , but also through stimulation of cholinergic and dopaminergic receptors (Bussolino etal., 1989) . In addition, PAF is associated with a wide variety of biological actions. Therefore, investigation concerning PAF is necessary for understanding platelet-blood vessel interaction abnormalities.
At first, the vasoconstrictive response to a pressor agent , NA, was explored under condi tions stimulating autologous platelets by PAF. PAF did not have any influences on NA-R in the absence of platelets, whereas NA showed two different response types , i.e., gradually attenuated response and non-attenuated response in the presence of platelets . These data seem to suggest that NA-R in the presence of platelets is markedly affected by what kinds of vasoactive substances are liberated from platelets activated by agonists. NA-R is assumed to be markedly affected by the vasoactive substances that are more preponderant. Surprisingly, as can be seen in Fig.3 and Fig.4 , this gradually attenuated response to NA was reversed to the initial augmented response following application of TTX (Michibayashi 1997 ), a Na-spike inhibitor (Hodgkin et al., 1952; Hagiwara 1983; Benoit et al., 1985) , while TTX did not suppress NA-R, i.e., post-junctional action of exogenous NA, but inhibited the perivascular autonomic nerves excitation of the rabbit ear central artery (Michibayashi 1983) . It has been already reported in the experiment using similarly isolated perfused artery, that a high dose of NA (50ng) caused gradually augmented responses (Michibayashi 1984) , although this result is not always applicable to experiments using low doses of NA. Thus, it is possible to assume that the gradually attenuated response to low doses of NA (Fig.1) intimately relates to the action of neurotransmitters released from the intrinsic vasodepressor nerve endings. So, when the inhibitory action of these neurotransmitters on NA-R is relatively weak, it is possible to predict that gradually attenuated responses may commonly occur at the lower dose of NA rather than its high dose.
To date, the vasoactive substances mediating vasodilator response through perivascular autonomic nerves are known to be acetylcholine (ACh) (Rand et al., 1970; Steinsland et al., 1973; Allen et al., 1975; Shepherd et al., 1978; Kuriyama et al., 1981; Fujii et al., 1992) , prostaglandin E (Stjarne 1973; Michibayashi 1983) , adenine nucleotides (Burnstock 1972; Su et al., 1978) , nitric oxide (Ralevic et al., 1991; Bennett et al., 1992; Liu et al., 1992) , and dopamine (Hope et al., 1978) . Regarding the gradually attenuated responses in the present study, ATP or a related purine derivative, a co-transmitter from perivascular adrenergic nerves, could be the vasoconstrictor in the rabbit ear artery. In addition, indomethacin, a cycloxygenase inhibitor, and NG-nitro-L-arginine, a nitric oxide synthetic inhibitor, did not show any reverse effect on gradually attenuated responses to NA (Mishibayashi 1997). Since ACh depresses the response to sympathetic nerve stimulation in the rabbit ear artery (Rand et al., 1970; Steinland et al. 1973; Allen et al., 1975) , modulation by ACh of adrenergic tranmission may be involved in this attenuated response.
Thus, it is possble to conclude that the gradually attenuated responses in the presence of platelets with PAF is perhaps linked to the neurotransmitter-releasing mechanism of perivas cular autonomic nerves by unknown substances liberated from platelets activated by PAF.
